Micro-cap neurodevelopment biotech PaxMedica files for a $17 million IPO - (NASDAQ via NewsPoints Desk)

  • PaxMedica filed with the US Securities and Exchange Commission to raise up to $17 million in an initial public offering, as reported in NASDAQ.

  • The company is testing its lead candidate PAX-101, an intravenous formulation of suramin, in a Phase IIB trial at six sites in South Africa for the treatment of autism spectrum disorder.

To read more NewsPoints articles, click here.